Carbalastine bitartrate, a new Alzheimer's drug of Huahai pharmaceutical, has obtained clinical approval
-
Last Update: 2014-09-15
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
According to the public information, carbalatin bitartrate is an acetylcholinesterase inhibitor, which is the mainstream drug for the treatment of Alzheimer's disease The original manufacturer is Novartis The experimental data showed that kabalatin tartrate was well tolerated to mild and moderate Alzheimer's disease due to no metabolism of liver and P450 (cytochrome) It was highly evaluated in a prospective, randomized, multicenter, double-blind study conducted in 45 countries including Europe and the United States According to information on CFDA website, at present, the domestic market of kabalanine bitartrate is monopolized by Novartis The enterprises in the process of product research and development also include Enhua Pharmaceutical (002262 SZ), Shanghai Sanwei pharmaceutical, vante pharmaceutical, etc Huahai Pharmaceutical Co., Ltd is mainly engaged in Puli and sartan type hypertension APIs, and is actively transforming to preparations Domestic preparations are an important strategic layout of the company
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
